{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T01:54:04Z","timestamp":1794966844891,"version":"4.9.1"},"reference-count":47,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,7]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>NXT007 is a next-generation, activated factor VIII (FVIIIa)\u2013mimetic bispecific antibody under investigation in the phase 1\/2 NXTAGE trial. Here, we report the primary analysis of the multiple-ascending-dose Part B study in people with hemophilia A (PwHA). Eligible participants were men with severe HA without FVIII inhibitors. Four dose cohorts (B1-B4) were planned, with NXT007 administered subcutaneously at maintenance doses of 0.072 mg\/kg, 0.28 mg\/kg, 0.70 mg\/kg, and 1.08 mg\/kg, respectively, every 4 weeks. Primary end points were safety (adverse events [AEs] and serious AEs [SAEs]), tolerability, pharmacokinetics, pharmacodynamics, and efficacy; secondary end points included incidence of anti-drug antibodies (ADAs). Participants in cohorts B1 (n = 10), B2 (n = 6), B3 (n = 6), and B4 (n = 8) had received NXT007 for a median (minimum to maximum) of 114.1 (29-140), 96.4 (88-112), 58.1 (52-72), and 22.2 (4-28) weeks, respectively. Two participants discontinued treatment: NXT007-unrelated AE (n = 1) and complete loss of NXT007 exposure due to ADAs (n = 1). Participants\u2019 plasma NXT007 concentration showed a dose-dependent increase, and predicted FVIII-equivalent activity reached a nonhemophilic level (\u226540 IU\/dL) in B2 onward. NXT007 had a favorable safety profile at all doses. Most AEs were mild\/moderate and all 3 SAEs were considered unrelated to NXT007. Mean annualized treated bleed rates were 1.48 (B1), 0.28 (B2), 0.00 (B3), and 0.00 (B4). Two participants had pharmacokinetics-affecting NXT007 ADAs, including the B1 participant who discontinued treatment. NXTAGE Part B demonstrates that NXT007 could provide nonhemophilic coagulation activity in PwHA, with a less burdensome dose regimen than currently available therapies. This trial was registered at Japan Registry of Clinical Trials as jRCT2080224835.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025031894","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T21:55:39Z","timestamp":1770328539000},"page":"2261-2271","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["NXTAGE: a phase 1\/2 study of NXT007 to assess safety, pharmacokinetics, and efficacy in hemophilia A without inhibitors"],"prefix":"10.1182","volume":"147","author":[{"given":"Keiji","family":"Nogami","sequence":"first","affiliation":[{"name":"1Department of Pediatrics, Nara Medical University, Nara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chur-Woo","family":"You","sequence":"additional","affiliation":[{"name":"2Department of Pediatrics, Daejeon Eulji Medical Center, Eulji University School of Medicine, Daejeon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6643-4245","authenticated-orcid":false,"given":"Young-Shil","family":"Park","sequence":"additional","affiliation":[{"name":"3Department of Pediatrics, Kyung Hee University Hospital at Gangdong, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6751-7723","authenticated-orcid":false,"given":"Yeu-Chin","family":"Chen","sequence":"additional","affiliation":[{"name":"4Hemophilia Care and Research Center, Tri-Service General Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7789-2148","authenticated-orcid":false,"given":"Ming-Ching","family":"Shen","sequence":"additional","affiliation":[{"name":"5Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7908-4969","authenticated-orcid":false,"given":"Jiaan-Der","family":"Wang","sequence":"additional","affiliation":[{"name":"6Center for Rare Disease and Hemophilia, Taichung Veterans General Hospital, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9348-9815","authenticated-orcid":false,"given":"Masahiro","family":"Takeyama","sequence":"additional","affiliation":[{"name":"7Division of Hemophilia, National Hospital Organization, Osaka National Hospital, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kagehiro","family":"Amano","sequence":"additional","affiliation":[{"name":"8Department of Laboratory Medicine, Tokyo Medical University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4121-019X","authenticated-orcid":false,"given":"Sheng-Chieh","family":"Chou","sequence":"additional","affiliation":[{"name":"9Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9181-1604","authenticated-orcid":false,"given":"Takuya","family":"Miwa","sequence":"additional","affiliation":[{"name":"10Chugai Pharmaceutical Co, Ltd, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3775-0704","authenticated-orcid":false,"given":"Chun-An","family":"Chen","sequence":"additional","affiliation":[{"name":"10Chugai Pharmaceutical Co, Ltd, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Miyake","sequence":"additional","affiliation":[{"name":"10Chugai Pharmaceutical Co, Ltd, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Iwasaki","sequence":"additional","affiliation":[{"name":"10Chugai Pharmaceutical Co, Ltd, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5204-2064","authenticated-orcid":false,"given":"Ryota","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"10Chugai Pharmaceutical Co, Ltd, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5922-7061","authenticated-orcid":false,"given":"Midori","family":"Shima","sequence":"additional","affiliation":[{"name":"1Department of Pediatrics, Nara Medical University, Nara, Japan"},{"name":"11Thrombosis and Hemostasis Research Center, Nara Medical University, Nara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"10040","key":"2026050711220101900_bib1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0140-6736(15)01123-X","article-title":"The past and future of haemophilia: diagnosis, treatments, and its complications","volume":"388","author":"Peyvandi","year":"2016","journal-title":"Lancet"},{"issue":"suppl 6","key":"2026050711220101900_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"issue":"1","key":"2026050711220101900_bib3","doi-asserted-by":"crossref","first-page":"102648","DOI":"10.1016\/j.rpth.2024.102648","article-title":"Extending health equity to people with moderate and mild hemophilia A: revisiting the HAVEN 6 trial","volume":"9","author":"Hermans","year":"2025","journal-title":"Res Prac Thromb Haemost"},{"issue":"4","key":"2026050711220101900_bib4","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3390\/jcm12041368","article-title":"Mild and moderate hemophilia A: neglected conditions, still with unmet needs","volume":"12","author":"Castaman","year":"2023","journal-title":"J Clin Med"},{"key":"2026050711220101900_bib5","unstructured":"National Bleeding Disorders Foundation\n          . MASAC Document 267 - MASAC Recommendation Concerning Prophylaxis for Hemophilia A and B with and without Inhibitors. Accessed 12 February 2026. https:\/\/www.bleeding.org\/healthcare-professionals\/guidelines-on-care\/masac-documents\/masac-document-267-masac-recommendation-concerning-prophylaxis-for-hemophilia-a-and-b-with-and-without-inhibitors."},{"issue":"3","key":"2026050711220101900_bib6","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/hae.14270","article-title":"Health-related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors-A non-interventional study","volume":"27","author":"Oldenburg","year":"2021","journal-title":"Haemophilia"},{"issue":"8","key":"2026050711220101900_bib7","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1080\/17474086.2023.2223925","article-title":"Efanesoctocog alfa for the prevention and treatment of bleeding in patients with hemophilia A","volume":"16","author":"Konkle","year":"2023","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"2026050711220101900_bib8","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1111\/hae.14297","article-title":"Confirmed long-term safety and efficacy of prophylactic treatment with BAY 94-9027 in severe haemophilia A: final results of the PROTECT VIII extension study","volume":"27","author":"Reding","year":"2021","journal-title":"Haemophilia"},{"issue":"13","key":"2026050711220101900_bib9","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1182\/blood.2020005673","article-title":"Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study","volume":"137","author":"Klamroth","year":"2021","journal-title":"Blood"},{"issue":"4","key":"2026050711220101900_bib10","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2209226","article-title":"Efanesoctocog alfa prophylaxis for patients with severe hemophilia A","volume":"388","author":"von Drygalski","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"2026050711220101900_bib11","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/hae.12905","article-title":"Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis","volume":"22","author":"Valentino","year":"2016","journal-title":"Haemophilia"},{"issue":"7","key":"2026050711220101900_bib12","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.3324\/haematol.2019.241554","article-title":"Factor VIII activity and bleeding risk during prophylaxis for severe hemophilia A: a population pharmacokinetic model","volume":"106","author":"Tiede","year":"2021","journal-title":"Haematologica"},{"issue":"16","key":"2026050711220101900_bib13","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1182\/bloodadvances.2018020552","article-title":"The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B","volume":"2","author":"Soucie","year":"2018","journal-title":"Blood Adv"},{"issue":"5","key":"2026050711220101900_bib14","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1055\/s-0040-1709519","article-title":"Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia A initiated on tertiary prophylaxis","volume":"120","author":"Chowdary","year":"2020","journal-title":"Thromb Haemost"},{"issue":"1","key":"2026050711220101900_bib15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2516.2010.02383.x","article-title":"Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels","volume":"17","author":"den Uijl","year":"2011","journal-title":"Haemophilia"},{"issue":"7","key":"2026050711220101900_bib16","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1160\/TH17-01-0030","article-title":"Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX\/IXa and X\/Xa, emicizumab, depends on its ability to bridge the antigens","volume":"117","author":"Kitazawa","year":"2017","journal-title":"Thromb Haemost"},{"issue":"13","key":"2026050711220101900_bib17","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/blood-2015-06-650226","article-title":"A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects","volume":"127","author":"Uchida","year":"2016","journal-title":"Blood"},{"issue":"9","key":"2026050711220101900_bib18","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/17512433.2023.2243213","article-title":"Clinical pharmacology of emicizumab for the treatment of hemophilia A","volume":"16","author":"Yoneyama","year":"2023","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"24","key":"2026050711220101900_bib19","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1182\/bloodadvances.2022007458","article-title":"Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies","volume":"6","author":"Kruse-Jarres","year":"2022","journal-title":"Blood Adv"},{"key":"2026050711220101900_bib20","unstructured":"National Bleeding Disorders Foundation\n          . MASAC Document 268 - Recommendation on the Use and Management of Emicizumab-kxwh (Hemlibra\u00ae) for Hemophilia A with and without Inhibitors. Accessed 12 February 2026. https:\/\/www.hemophilia.org\/healthcare-professionals\/guidelines-on-care\/masac-documents\/masac-document-268-recommendation-on-the-use-and-management-of-emicizumab-kxwh-hemlibrar-for-hemophilia-a-with-and-without-inhibitors."},{"issue":"5","key":"2026050711220101900_bib21","doi-asserted-by":"crossref","first-page":"e12760","DOI":"10.1002\/rth2.12760","article-title":"Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: data on safety and effectiveness from phase 3 pivotal studies","volume":"6","author":"Chowdary","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"1","key":"2026050711220101900_bib22","doi-asserted-by":"crossref","first-page":"e202","DOI":"10.1111\/j.1365-2516.2009.02111.x","article-title":"Physical activity levels and participation in sport in Irish people with haemophilia","volume":"16","author":"Sherlock","year":"2010","journal-title":"Haemophilia"},{"issue":"6","key":"2026050711220101900_bib23","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1111\/hae.14866","article-title":"Targeting higher factor VIII levels for prophylaxis in haemophilia A: a narrative review","volume":"29","author":"Malec","year":"2023","journal-title":"Haemophilia"},{"issue":"1","key":"2026050711220101900_bib24","doi-asserted-by":"crossref","first-page":"010","DOI":"10.1055\/s-0044-1796629","article-title":"The evolution of hemophilia pharmacological treatments and therapeutic targets at the turn of the third millennium","volume":"51","author":"Coppola","year":"2025","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"2026050711220101900_bib25","doi-asserted-by":"crossref","first-page":"2222441","DOI":"10.1080\/19420862.2023.2222441","article-title":"Efficient production of bispecific antibody by FAST-IgTM and its application to NXT007 for the treatment of hemophilia A","volume":"15","author":"Koga","year":"2023","journal-title":"MAbs"},{"issue":"2","key":"2026050711220101900_bib26","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jtha.2023.09.034","article-title":"A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic state","volume":"22","author":"Teranishi-Ikawa","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2026050711220101900_bib27","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1080\/19420862.2017.1314873","article-title":"Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibody","volume":"9","author":"Maeda","year":"2017","journal-title":"MAbs"},{"issue":"suppl 1","key":"2026050711220101900_bib28","doi-asserted-by":"crossref","first-page":"11295","DOI":"10.1182\/blood-2022-155918","article-title":"Quantitative estimation of the in vivo equivalent factor VIII activity of NXT007, an emicizumab-based, next-generation, activated factor VIII-mimetic bispecific antibody, from nonclinical data [abstract]","volume":"140","author":"Yoneyama","year":"2022","journal-title":"Blood"},{"issue":"4","key":"2026050711220101900_bib29","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1182\/bloodadvances.2025018215","article-title":"Next-generation FVIIIa-mimetic bispecific antibody NXT007: evaluation in preclinical models of hemostasis and thrombosis","volume":"10","author":"Locke","year":"2026","journal-title":"Blood Adv"},{"issue":"10","key":"2026050711220101900_bib30","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1016\/j.jtha.2025.06.013","article-title":"A first-in-human study of NXT007, a next-generation, activated factor VIII-mimetic bispecific antibody, in healthy participants","volume":"23","author":"Sambe","year":"2025","journal-title":"J Thromb Haemost"},{"issue":"11","key":"2026050711220101900_bib31","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/jth.12672","article-title":"Definitions in hemophilia: communication from the SSC of the ISTH","volume":"12","author":"Blanchette","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2026050711220101900_bib32","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1365-2516.2006.01202.x","article-title":"Current co-ordinated activities of the PEDNET (European Paediatric Network for Haemophilia Management)","volume":"12","author":"Donadel-Claeyssens","year":"2006","journal-title":"Haemophilia"},{"issue":"9","key":"2026050711220101900_bib33","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"issue":"suppl 3","key":"2026050711220101900_bib34","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/hae.14976","article-title":"Benefits and risks of non-factor therapies: redefining haemophilia treatment goals in the era of new technologies","volume":"30","author":"Mancuso","year":"2024","journal-title":"Haemophilia"},{"issue":"9","key":"2026050711220101900_bib35","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2216455","article-title":"Phase 3 trial of concizumab in hemophilia with inhibitors","volume":"389","author":"Matsushita","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"2026050711220101900_bib36","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/bjh.18495","article-title":"Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: phase II study results","volume":"200","author":"Mahlangu","year":"2023","journal-title":"Br J Haematol"},{"issue":"10386","key":"2026050711220101900_bib37","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(23)00284-2","article-title":"Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial","volume":"401","author":"Young","year":"2023","journal-title":"Lancet"},{"issue":"5","key":"2026050711220101900_bib38","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1016\/S2352-3026(23)00037-6","article-title":"Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A\/B): a multicentre, open-label, randomised, phase 3 trial","volume":"10","author":"Srivastava","year":"2023","journal-title":"Lancet Haematol"},{"issue":"4","key":"2026050711220101900_bib39","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jtha.2023.12.016","article-title":"FRONTIER1: a partially randomized phase 2 study assessing the safety, pharmacokinetics, and pharmacodynamics of Mim8, a factor VIIIa mimetic","volume":"22","author":"Lentz","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"9","key":"2026050711220101900_bib40","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"2026050711220101900_bib41","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/1076029607309176","article-title":"Elevated levels of prothrombin fragment 1 + 2 indicate high risk of thrombosis","volume":"14","author":"Ota","year":"2008","journal-title":"Clin Appl Thromb Hemost"},{"issue":"12","key":"2026050711220101900_bib42","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1182\/blood-2013-04-460147","article-title":"Biomarkers for prediction of venous thromboembolism in cancer","volume":"122","author":"Pabinger","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2026050711220101900_bib43","doi-asserted-by":"crossref","first-page":"102306","DOI":"10.1016\/j.rpth.2023.102306","article-title":"Pharmacokinetics and coagulation biomarkers in children and adults with hemophilia A receiving emicizumab prophylaxis every 1, 2, or 4 weeks","volume":"8","author":"Kiialainen","year":"2024","journal-title":"Res Prac Thromb Haemost"},{"issue":"1","key":"2026050711220101900_bib44","doi-asserted-by":"crossref","first-page":"102271","DOI":"10.1016\/j.rpth.2023.102271","article-title":"NXT007-mediated hemostatic potential is suppressed by activated protein C-catalyzed inactivation of activated factor V","volume":"8","author":"Nakajima","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"2026050711220101900_bib45","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.thromres.2024.03.021","article-title":"Antithrombin exhibits anticoagulant effects on the emicizumab-based engineered bispecific antibody (NXT007)-mediated blood coagulation","volume":"237","author":"Nakajima","year":"2024","journal-title":"Thromb Res"},{"issue":"6","key":"2026050711220101900_bib46","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1111\/hae.15106","article-title":"NXT007 does not interfere with the anticoagulant effects on tissue factor pathway inhibitor","volume":"30","author":"Nakajima","year":"2024","journal-title":"Haemophilia"},{"issue":"6","key":"2026050711220101900_bib47","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/hae.14398","article-title":"Low immunogenicity of emicizumab in persons with haemophilia A","volume":"27","author":"Schmitt","year":"2021","journal-title":"Haemophilia"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/19\/2261\/2517449\/blood_bld-2025-031894-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/19\/2261\/2517449\/blood_bld-2025-031894-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T15:22:14Z","timestamp":1778167334000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/19\/2261\/566441\/NXTAGE-a-phase-1-2-study-of-NXT007-to-assess"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":47,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026,5,7]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025031894","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,7]]},"published":{"date-parts":[[2026,5,7]]}}}